Cardiology Research and Practice

Research Article

Associations between β-Blocker Therapy at Discharge and Long-Term Follow-Up Outcomes in Patients with Unstable Angina Pectoris

Table 6

Multivariate Cox regression analysis of secondary endpoints in propensity score matching patients.


	Univariate		Multivariate
	HR (95% CI)	value	A		B
	HR (95% CI)	value	HR (95% CI)	value	HR (95% CI)	value

Age (years)	1.08 (1.06, 1.10)	<0.001	1.07 (1.05, 1.09)	<0.001	1.06 (1.04, 1.07)	<0.001
Male (%)	0.85 (0.63, 1.17)	0.320
Stroke (%)	1.90 (1.35, 2.68)	<0.001			1.47 (1.08, 1.98)	0.014
Heart rate (bpm)	1.02 (1.01, 1.03)	<0.001	1.02 (1.01, 1.03)	0.001	1.01 (1.00, 1.02)	0.030
hsCRP (mg/L)	1.02 (1.00, 1.05)	0.031
HbA₁C (%)	1.15 (1.04, 1.28)	0.008			1.19 (1.08, 1.30)	<0.001
LVEF ≥ 50%	Ref		Ref		Ref
40% ≤ LVEF < 50%	2.93 (1.59, 5.41)	0.001	2.23 (1.19, 4.16)	0.012	1.89 (1.07, 3.34)	0.029
LVEF < 40%	1.30 (0.32, 5.24)	0.714	1.19 (0.29, 4.87)	0.814	0.87 (0.21, 3.54)	0.845
LM (%)	2.47 (1.70, 3.61)	<0.001	1.62 (1.09, 2.39)	0.016	1.52 (1.08, 2.16)	0.017
Multivessels (%)	3.78 (2.05, 6.97)	<0.001	260 (1.39, 4.85)	0.003	2.22 (1.34, 3.69)	0.002
CTO (%)	2.42 (1.64, 3.58)	<0.001	1.71 (1.13, 2.57)	0.010
β-Blockers at discharge (%)	1.40 (1.03, 1.91)	0.033

A, present all-cause death/HF; B, present all-cause death/HF/nonfatal MI. MI, myocardial infarction; HbA_IC, glycosylated hemoglobin; hsCRP, hypersensitivity C-reactive protein; LVEF, left ventricular ejection fraction; LM, left main trunk; CTO, chronic total occlusions.